ReviewPediatric nephrology (Berlin, Germany)2009
Nephrotic syndrome and rituximab: facts and perspectives.
Review in Pediatric nephrology (Berlin, Germany), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 42 citations in OpenAlex.
- Rituximab efficiency in children with steroid-dependent nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2010Trial
- Rituximab experience in children with nephrotic syndrome: what have we observed differently.Turk pediatri arsivi · 2020Article
- Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome.Pediatric nephrology (Berlin, Germany) · 2019Observational
- The efficacy of rituximab in adult frequently relapsing minimal change disease.Clinical kidney journal · 2017Article
- A higher frequency of CD4⁺CXCR5⁺ T follicular helper cells in adult patients with minimal change disease.BioMed research international · 2014Article
- Long-term outcome of children treated with rituximab for idiopathic nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2013Article
- An unusual cause of severe persistent neutropenia in a child with nephrotic syndrome.BMJ case reports · 2013Article
- Outcome of severe steroid-dependent nephrotic syndrome treated with mycophenolate mofetil.Pediatric nephrology (Berlin, Germany) · 2013Article
- Hepatocellular carcinoma following renal transplantation.Gastrointestinal cancer research : GCR · 2011Article
- The factors that may predict response to rituximab therapy in recurrent focal segmental glomerulosclerosis: a systematic review.Journal of transplantation · 2011Article
- Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report.Clinical journal of the American Society of Nephrology : CJASN · 2010Article
- Pharmacotherapeutic review and update of idiopathic nephrotic syndrome in children.Pharmacy world & science : PWS · 2010Review
- Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine.Pediatric nephrology (Berlin, Germany) · 2010Article
- Cyclosporine A and steroid therapy in childhood steroid-resistant nephrotic syndrome.International journal of nephrology and renovascular disease · 2010Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic nephrotic syndrome is the most frequent glomerular disease that presents during childhood and is mainly due to minimal change nephropathy (MCNS) and focal-segmental glomerulosclerosis (FSGS). Its treatment is still challenging, with up to 50% of the patients who are initially steroid sensitive (usually MCNS) being frequent relapsers and requiring additional long-term immunosuppression. However, current immunosuppressive regimens are associated with severe toxicity. Only half of the steroid-resistant patients (usually FSGS) achieve long-term remission even with intensive immunosuppression and plasma exchange. Rituximab (RTX), a chimeric monoclonal antibody inhibiting CD20-mediated B-cell proliferation and differentiation, has recently gained attention as a potentially successful therapy for complicated idiopathic nephrotic syndrome in children. A number of case reports and one prospective non-controlled multicenter trial point to the beneficial effects of RTX as a rescue therapy in children with steroid/cyclosporine-dependent or -resistant nephrotic syndrome. However, publication bias often results in positive outcomes being more likely to be reported than negative ones and, in particular, the safety profile of this drug in this group of patients remains unclear. Therefore, controlled randomized studies are required to assess this issue, to develop treatment guidelines, to evaluate the therapeutic and economical efficacy, and to define criteria for the selection of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.